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Background: Pneumothorax is a feared complication of cystic fibrosis. With improved survival into adult life the incidence of pneumothorax is
expected to increase. The optimal management of these patients is unclear.
Methods: Case review of patients from the three Scottish adult CF centres.
Results: A total of 22 episodes of pneumothorax occurred in 20 patients over a 12 year period. 2 patients died as a result of the pneumothorax. 16
pneumothoraces were treated by insertion of an intercostal drain and 8 by observation. 8 patients suffered a prolonged air leak. 5 patients were
treated with pleurodesis. Pneumothorax was associated with a small decline in lung function which persisted for at least 1 year.
Conclusion: Pneumothorax can present a challenge to treat in adult CF. However successful outcomes can be achieved even in cases of prolonged
air leaks. Current national guidelines help in selecting optimal pleural interventions.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Pneumothorax is a recognised complication of cystic fibrosis
[1] (CF), presumably reflecting a weakening of the pleural
surface by underlying inflammation and sepsis, coupled with
the increased mechanical stress on the pleura in obstructive lung
disease. It has a reported incidence of 6 per 1000/year and
occurs more commonly in adult than paediatric patients [2].
With improved therapies, more patients are now surviving well
into adult life and therefore we would expect to see more
episodes of pneumothorax requiring treatment in adult centres.
The optimal management of these patients is uncertain and
recent evidence-based guidelines reflect the paucity of data on
these patients. Furthermore, much of the evidence is from
historical cohorts who do not reflect modern management
strategies either of the underlying cystic fibrosis or the acute
episode of pneumothorax with the introduction of small
diameter chest tubes.⁎ Corresponding author. Tel.: +44 1896 826000.
E-mail address: andrew.macduff@tesco.net (A. MacDuff).
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doi:10.1016/j.jcf.2010.04.005We therefore undertook a retrospective review of the
episodes of spontaneous pneumothorax from the Scottish
adult CF centres in recent years.2. Methods
Patients were identified from each of the 3 adult CF centres
in Scotland which together care for a population of 400 patients.
The case notes relating to the episode were reviewed by local
staff and the anonymised data were collected by one
investigator. Demographic data, spirometry 1 year before,
around the event (but not with drainage in situ) and 1 year
after the event, recent microbiology and the treatment details of
the pneumothorax episode and any ipsilateral recurrence were
recorded. As this was a retrospective audit of current practice
formal ethics review was not required. Statistical analysis was
performed using GraphPad Prism version 5 .01 (GraphPad
Prism Software Inc, La Jolla, Califronia, USA).3. Results
A total of 22 episodes (2 bilateral) occurred in 20 patients in
the period from July 1997 to July 2009. 9 patients were treatedd by Elsevier B.V. All rights reserved.
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patients had separate episodes of pneumothorax on the left and
right which were considered as individual episodes and not
recurrences. There were 13 males and 7 females. The mean age
at the time of pneumothorax was 23 years. The incidence of
spontaneous pneumothorax in this population was therefore
approximately 4.6 per 1000/year.
It was not possible from the case record to determine the
interval between the occurrence of the pneumothorax and the
first treatment as the symptoms experienced were frequently
similar to an exacerbation of airways disease and the
pneumothorax was only discovered on chest radiograph. Two
patients (both aged 19 years) died during the admission with
pneumothorax (mortality in this series was 10%). The median
length of follow up was 2.5 years for event survivors (range
0.06–7.3 years). There are currently 15 survivors and 1 has
undergone lung transplantation.
Patients had severe airflow limitation, with average FEV1
1 year before the episode of 40% predicted (range 17.3–89.6,
recorded 349 days before event on average). There were 13
right sided and 11 left sided events. Two patients were current
smokers. Fourteen patients were colonised with Pseudomonas
aeruginosa, 3 with Burkholderia complex, 8 with Staphylococ-
cus aureus (including 1 MRSA), 1 with Stenotrophomonas
maltophilia and 1 Aspergillus fumigatus. Twelve patients were
receiving long term macrolides, 10 nebulised DNase, 4
nebulised colomycin and 1 nebulised tobramycin.
The median length of stay was 13 days (range 4–128 days).
The managing clinicians estimate of the size of pneumothorax
was documented in 15 patients (in further 2 cases it was
described as large, both were treated by intercostal drainage),
median 40% (range 5–70%).
16 episodes were treated by insertion of an intercostal tube,
8 by observation without intervention and none was managed
by needle aspiration.
In line with standard UK practice all patients were initially
treated as in-patients with appropriate intravenous antibiotics
(based on sputum sensitivity patterns), chest physiotherapy and
dietician input. Analgesia was given as required.
3.1. Active treatment
In 14 of the 16 patients treated with intercostal drainage the
size of the drain was recorded. 8 patients were successfully
managed by small bore (8–14 French) drains. 4 of the 16
patients required the insertion of a second drain. All these
patients survived. None required a third pleural procedure. The
median length of drainage was 6.4 days (range 2–42 days).
A persistent pneumothorax can be defined as ongoing air
leak for over 5 days [2]. In this series 8 patients (36% of
episodes of the total) had an air leak that persisted for 5 days or
more. 2 of these patients were discharged home with an
intercostal drain in situ attached to a flutter valve, including one
who was discharged home for palliative care. Both patients who
died as a result of the pneumothorax had a prolonged air leak
(12 and 42 days). 6 patients survived a prolonged air leak and
this includes 3 patients with very prolonged leaks (15, 20 and28 days). One of these required surgical intervention with
concurrent pleurodesis. The median length of follow up for
survivors of prolonged air leak was 3.45 years (range 0.1–
5.8 years). 5 of these 6 patients are still alive. The other died
5.8 years after the event.
A total of 5 patients underwent pleurodesis during the index
admission, 3 surgically, and two with talc or kaolin. Six patients
were treated with wall suction for an average duration of 57 h.
There were no recorded complications associated with drain
insertion.
3.2. Conservative management
All 8 patients treated by observation survived and no patient
initially treated by observation required insertion of a chest
drain.
3.3. Recurrence
There were 9 ipsilateral recurrences (41% of the total; 6 in
the drainage group and 3 in the observation group). The median
time to recurrence was 3 months (range 11 days–46 months)
after the index event.
3.4. Pulmonary function data
Lung function data were available at all 3 time points in 17
patients (see Table 1). Around the time of the event there was a
decrease in FEV1 which did not recover up to 1 year afterwards.
There was no correlation between pneumothorax size and
preceding pulmonary function in the patients for whom these
data were available (Spearman correlation coefficient r=0.24).
4. Discussion
Pneumothorax is viewed as a potentially catastrophic event
in cystic fibrosis that requires a prolonged in-patient stay with
prolonged chest tube drainage and a significant associated
mortality. This study is the largest modern review of the impact
and management of spontaneous first pneumothorax in adult CF
patients in the UK. It confirms the safety of “active” observation
in selected patients (b30% estimated size) and the use of small
bore intercostal drains in a population where there is often a
concern regarding the ability of small bore drains to cope with
the potentially large air leaks encountered in this group. The
estimated incidence of 4.6/1000/year is similar to the 6/1000/yr
reported by Flume et al. [2] for the period 1990–1999. The
mean age of our population (23 years) was also similar to the
21.9 reported by the US group [1]. The male preponderance of
patients (1.85 M:1F) in this study confirms the recognised
increased frequency of spontaneous pneumothorax in males in
both the CF community [2,3] and the general adult population
[4].
The largest UK series of CF associated pneumothorax (first
and recurrent events) reported a mortality of 15% over the
period 1965–1981 [3] in this series the mortality associated with
pneumothorax was less. A recent report from a paediatric centre
Table 1
Serial lung function on 14 patients with complete data available.
Patient FEV1(l) 1 year
before Ptx
Time before
Ptx(days)
FEV1(l) at
time Ptx
Time before
Ptx(days)
FEV1(l) 1 year
after Ptx
Time after
Ptx(days)
% pred FEV1
before Ptx
% pred FEV1
at Ptx
% pred FEV1
1 year after
1 3.82 −572 4.71 −297 4.7 452 74.9 92.4 89.6
1 4.57 −400 4.59 249 4.13 475 89.6 90 81
2 1.34 −384 0.88 −35 0.94 229 28.5 18.7 20
2 1.73 −354 0.94 −201 1.04 95 36.8 20 22.1
3* 1.41 −357 0.84 −13 0.94 399 56.4 33.6 37.6
3* 1.41 −357 0.84 −13 0.94 399 56.4 33.6 37.6
4 2.39 −162 2.64 −70 1.8 365 55 61.4 41.9
5 0.73 −337 0.66 −92 0.57 335 23.5 21.3 18.4
6 0.82 −265 1 −27 0.87 408 35.1 43 37
7 0.81 −397 1.14 66 0.8 365 25.1 36 25.1
8 2.45 −399 1.8 −64 1.54 362 59.1 43 37.1
9 0.68 −229 0.8 0 0.77 340 19.1 22 22
10 1.31 −324 0.91 31 1.68 395 30 21.1 39
11 0.87 −349 0.96 39 0.6 358 24 27 17
12 1.96 −334 2.21 −5 1.56 380 46 52 37
13 0.95 −308 0.85 −112 0.85 252 23 21 21
14 1.95 −364 0.75 28 1.3 504 48 23 39
Mean 1.72 −346.6 1.56 −30.4 1.47 359.6 43 38.7 36.6
3* Simultaneous bilateral pneumothoraces.
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et al. [1] did not report the mortality associated with the
pneumothorax episode but found that pneumothorax was
associated with a significantly increased risk of death in the
study period. In the current study both patients who died during
the pneumothorax episode had a prolonged air leak that failed to
heal. The management of prolonged air leak in these patients is
difficult as they are often not fit enough for surgical
intervention.
A possible answer in these difficult cases is to attach the
intercostal drain to a flutter valve to allow easier ambulation and
physiotherapy and also in selected cases discharged home,
particularly in patients with advanced disease who are not fit for
surgery. This approach was used successfully in 2 patients in
this study neither of whom was fit for surgical treatment. One
survived the pneumothorax episode but died 7 months later.
The other died at home with the intercostal drain in place
(6 weeks after the index admission).
The median length of hospital in-patient stay was 13 days but
in some patients there were prolonged admissions (up to
4 months in one case). The length of stay for CF patients with
pneumothorax has not previously been described but is
significantly longer than that for primary spontaneous pneu-
mothorax [6]. Nebulised therapies have been reported to be
associated with an increased risk of pneumothorax [1]. They
were commonly seen in this study but whether they are an
independent risk or simply reflected the severity of the
underlying airways disease in our patients is not known.
The use of sclerosants or surgery to obliterate the pleural
space in CF patients remains an area of uncertainty because of
concerns regarding future need for lung transplantation. Smythe
et al. [7] reported increased haemorrhagic complications in
patients undergoing lung removal during transplant who had
previously undergone pleurodesis. A recent review suggests
that these concerns are over estimated with modern transplan-tation techniques [8]. Current advice from our regional
transplant unit is that if pleurodesis is required then medical
pleurodesis should be undertaken. If a surgical approach is
required, apical pleural abrasion rather than pleurectomy is
preferred.
Our study shows that observation of small (30% or less)
pneumothorax is successful and none of these patients required
subsequent insertion of an intercostal drain. In agreement with
the management of primary spontaneous pneumothorax, in CF
patients with larger pneumothoraces, the use of small bore
drains is often successful and the routine insertion of large (24Fr
or greater) appears to be unnecessary. Wall suction may aid
resolution but is not needed in the majority of patients. There is
little data on the optimum management of the pleural airleak
itself in CF patients. Previous studies do not describe the
interventions used [2] nor the size of intercostal drain inserted
[3,5]. Guidelines published by national committees extrapolate
from studies conducted in primary spontaneous pneumothorax
[9].
In this study of adult patients, pneumothorax occurs in
patients with severe airflow limitation and advanced disease
characterised by the colonisation by multi-drug resistant
organisms. A high proportion of the patients were using
DNase and this has previously been associated with an
increased risk of pneumothorax [2] but this is likely to reflect
more advanced lung disease rather than a causal link.
Previous studies have found that pneumothorax is associated
with a significant decline in lung function that persists for at least
one year [2,5]. In this cohort we saw a small decline (average 4%)
however this decline did persist for at least one year.
Pneumothorax is an uncommon but potentially serious
complication of cystic fibrosis. However, the majority of
patients can be treated successfully by medical management,
either by “active” observation in the case of small relatively
asymptomatic pneumothoraces or by the insertion of small bore
249A. MacDuff et al. / Journal of Cystic Fibrosis 9 (2010) 246–249drains. The decline in lung function associated with the event is
small and largely recovers a year after the event. Prolonged air
leak remains the most serious management challenge but
successful outcomes and long term survival do occur.
Our study confirms the usefulness of current guidelines in
the management of pneumothorax in CF patients.
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